Document is current
Any future updates will be listed below
-
Authors
Mohammedi, Kamel
Pigeyre, Marie
Bosch, Jackie
Yusuf, Salim
Gerstein, Hertzel C.
- License Information
-
More Information
Article History
Received: 21 June 2024
Accepted: 30 July 2024
First Online: 3 September 2024
Declarations
:
: The protocols of ORIGIN, ONTARGET and TRANSCEND trials were approved by the ethics committee at each study site, and all participants provided written informed consent.
: Not applicable.
: K.M. reports consulting fees from Novo Nordisk; honoraria for lectures, presentations, or speaker bureaus from Novo Nordisk, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Sanofi, Lifescan, Abbott, and Bayer; and participation to Advisory Board from Novo Nordisk, Sanofi and Amarin. M.P. declares no conflicts of interest. J.B. reports personal fees from Bayer AG for event adjudication. S.Y. declares no conflicts of interest. HCG holds the McMaster-Sanofi Population Health Institute Chair in Diabetes Research and Care. He reports research grants from Eli Lilly, Novo Nordisk, and Sanofi; honoraria for speaking from Astra Zeneca, Eli Lilly, Novo Nordisk, Sanofi, Zuellig, and Jiangsu-Hansen; and consulting fees from Abbott, Eli Lilly, Novo Nordisk, Sanofi, Pfizer, Boehringer Ingelheim, Kowa and Hanmi.
